AMAZING ISRAEL: THERAPAEUTIC VACCINE TO PREVENT RECURRENCE OF CANCER ****
http://www.ynetnews.com/articles/0,7340,L-4170853,00.html
BOYCOTT THIS YOU BDS BASTARDS! rsk
Vaxil BioTherapeutics, a biotechnical company based in Ness Ziona,
near Tel Aviv, has produced a ground-breaking therapeutic vaccine for
cancer patients which could prevent about 90% of cancers from coming
back.
Vaxil was founded in 2006 by Dr. Lior Carmon and the vaccine is now in
clinical trials at the Hadassah University Medical Center in
Jerusalem. The vaccine could be available as early as 2017 to
administer on a regular basis, not only to help treat cancer but in
order to keep the disease from recurring.
The vaccine is being tested against a type of blood cancer, ‘multiple
myeloma’. If the substance works as hoped, its platform technology,
VaxHit could be applied to 90% of all known cancers, including
prostate and breast cancer, solid and non-solid tumors.
“In cancer, the body knows something is not quite right but the immune
system doesn’t know how to protect itself against the tumor like it
does against an infection or virus. This is because cancer cells are
the body’s own cells gone wrong,” says Julian Levy, the company’s CFO.
“Coupled with that, a cancer patient has a depressed immune system,
caused both by the illness and by the treatment.” The trick is to
activate a compromised immune system to mobilize against the threat.
A traditional vaccine helps the body’s immune system fend off foreign
invaders such as bacteria or viruses, and is administered to people
who have not yet had the ailment. Therapeutic vaccines, like the one
Vaxil has developed, are given to sick people, and work more like a
drug.
The new vaccine works by activating the immune system by “training”
T-cells to search and destroy cells with the MUC1 molecule, typically
found only on cancer cells. More than 90% of common solid tumor
cancers bear the MUC1 molecule, as well as many non-solid tumors,
including lymphoma, leukemia and multiple myeloma.
Advanced-stage cancer will still require chemotherapy or surgery to
remove a large tumor, Vaxil CEO Julian Levy noted, but if the cancer
is brought down to size, the body will then be able to fight it, with
ImMucin seen as a long-term approach to prevent recurrence.
According to Data Monitor, the value of the market for cancer vaccines
is expected to reach $4-5 billion by 2014.
Reprinted with permission from Shalom Life
Comments are closed.
